Abstract 449P
Background
Improved cancer survival rates have escalated the demand for sustainable supportive care for survivors. Nasopharyngeal cancer (NPC) survivors often grapple with lasting radiation side effects. The M. D. Anderson Symptom Inventory - Head & Neck Module - Chinese version (MDASI-HN-C) has previously been validated for NPC patients undergoing radiation therapy (RT), but not for survivors. This study aims to psychometrically validate the MDASI-HN-C for NPC survivors.
Methods
In this single-centre cross-sectional study, 200 NPC survivors who completed RT with or without chemotherapy between three and 120 months were surveyed. The internal consistency reliability, convergent, and construct validity of the MDASI-HN-C were evaluated using Cronbach’s alpha (α) test, Pearson’s correlation (r), and exploratory factor analysis (EFA), respectively.
Results
All three subscales of the MDASI-HN-C exhibited strong internal consistency, with α ranging from 0.855 to 0.911. The MDASI-HN-C subscales were negatively correlated with the total score (r = -0.538 to -0.612; all p < 0.001), physical (r = -0.679 to -0.787; all p < 0.001), emotional (r = -0.536 to -0.625; all p < 0.001), functional (r = -0.307 to -0.390; all p < 0.001), and HN-specific (r = -0.587 to -0.616; all p < 0.001) domains of the Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN) scale. No correlations were identified between any subscales and the social/family domain. The MDASI-HN-C subscales were also positively correlated with the total score of the Cancer Survivors’ Unmet Needs Measure (CaSUN) (r = 0.414 to 0.468; all p < 0.001). Two factors for the 13 core items were identified by EFA, while only one factor each was found for the HN-specific and interference items. Noteworthily, open-ended responses indicated significant concerns about hearing loss and tinnitus among NPC survivors.
Conclusions
The MDASI-HN-C is a robust tool with satisfactory psychometric properties for assessing symptom burden among NPC survivors. The inclusion of 'hearing problems' as an additional item would enhance its applicability by capturing sensorial disturbances that significantly affect this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract